A US-based neurologist KOL discusses their approach to treating agitation in Alzheimer’s disease. This KOL provides insight on the rollout of Leqembi and how this drug compares to pipeline therapy donanemab and also shares their opinions on potential targets for future Alzheimer’s treatment.

This interview was conducted on 19 January 2024.

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal .

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.